[go: up one dir, main page]

TR200101755T2 - Tricyclic farnesyl protein transferase inhibitors. - Google Patents

Tricyclic farnesyl protein transferase inhibitors.

Info

Publication number
TR200101755T2
TR200101755T2 TR2001/01755T TR200101755T TR200101755T2 TR 200101755 T2 TR200101755 T2 TR 200101755T2 TR 2001/01755 T TR2001/01755 T TR 2001/01755T TR 200101755 T TR200101755 T TR 200101755T TR 200101755 T2 TR200101755 T2 TR 200101755T2
Authority
TR
Turkey
Prior art keywords
protein transferase
farnesyl protein
group
transferase inhibitors
compounds
Prior art date
Application number
TR2001/01755T
Other languages
Turkish (tr)
Inventor
G. Taveras Arthur
J. Doll Ronald
B. Cooper Alan
A. Ferreira Johan
Guzi Timothy
K. Mallams Alan
F.Rane Dinanath
M. Girijavallabhan Viyyoor
Afonso Adriano
J. Aki Cynthia
Chao Jianping
Alvarez Carmen
M. Kelly Joseph
Lalwani Tarik
A. Desai Jagdish
J. S. Wang James
Weinstein Jay
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of TR200101755T2 publication Critical patent/TR200101755T2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Formül (1.0)bilesikleri açiklanmaktadir; burada R13 bir imidazol halkasini temsil eder;R14 bir karbamat, üre,amit veya sülfonamit grubunu temsil eder; amit gurubu ile R13 imidazol grubu arasindaki alkil zinciri ikameli oldugunda R8 H'yi temsil eder veya R8 arilalkil, heteroarilalkil veya sikloalkil gibi bir ikameyi temsil eder;ve kalan ikameler burada tanimlandigi gibidir. Ayrica R8'in H ve amit grubu ile R13 imidazol grubu arasindaki alkil zincirinin ikamesiz oldugu bilesikler açiklanmaktadir. Ayrica açiklanan bilesikleri kullanarak kanseri tedavi etmek için bir yöntem ve farnezil protein transferazi inhibe etmek için bir yöntem açiklanmaktadir.The compounds of formula (1.0) are described; wherein R13 represents an imidazole ring, R14 represents a carbamate, urea, amide or sulfonamide group; When the alkyl chain between the amide group and the R13 imidazole group is substituted, R8 represents H, or R8 represents a substituent such as arylalkyl, heteroarylalkyl or cycloalkyl, and the remaining substituents are as defined herein. Also disclosed are compounds in which the alkyl chain between R8's H and amide group and R13 imidazole group is unsubstituted. Also disclosed is a method for treating cancer using the compounds described, and a method for inhibiting farnesyl protein transferase.

TR2001/01755T 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors. TR200101755T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21639898A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
TR200101755T2 true TR200101755T2 (en) 2001-09-21

Family

ID=22806914

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01755T TR200101755T2 (en) 1998-12-18 1999-12-16 Tricyclic farnesyl protein transferase inhibitors.

Country Status (20)

Country Link
EP (1) EP1140902A1 (en)
JP (1) JP2002533336A (en)
KR (1) KR20010081116A (en)
CN (1) CN1326850C (en)
AR (1) AR021718A1 (en)
AU (1) AU776558B2 (en)
BR (1) BR9916314A (en)
CA (1) CA2354779A1 (en)
CO (1) CO5160350A1 (en)
CZ (1) CZ20011950A3 (en)
HU (1) HUP0202152A2 (en)
IL (1) IL143408A0 (en)
NO (1) NO20012961L (en)
NZ (1) NZ511878A (en)
PE (1) PE20001342A1 (en)
PL (1) PL348293A1 (en)
SK (1) SK7592001A3 (en)
TR (1) TR200101755T2 (en)
WO (1) WO2000037459A1 (en)
ZA (1) ZA200104233B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9916314A (en) 1998-12-18 2001-10-02 Schering Corp Tricyclic farnesyl transferase protein inhibitors
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
WO2002056884A2 (en) * 2001-01-22 2002-07-25 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
AU2002257114A1 (en) * 2001-04-06 2002-10-21 Schering Corporation Treatment of malaria with farsenyl protein transferase inhibitors
CA2590979A1 (en) 2004-12-13 2006-06-22 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
MX2007007078A (en) 2004-12-14 2007-09-04 Schering Corp Farnesyl protein transferase inhibitors and methods for treating proliferative diseases.
JP2009523799A (en) * 2006-01-19 2009-06-25 シェーリング コーポレイション Piperazine derivatives as farnesyl protein transferase inhibitors
US9914726B2 (en) 2014-03-19 2018-03-13 Vps-3, Inc. 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1H-tetrazol-1-yl)propan-2-ols and processes for their preparation
CN106132947B (en) 2014-03-19 2019-08-09 Vps-3有限公司 Preparation method of compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Pharmaceutical compositions for inhibition of g-protein function and for treatment of proliferative diseases containing tricyclic compounds some such compounds and process for preparing part of them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL117798A (en) * 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases and pharmaceutical compositions comprising them
US5801175A (en) * 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
PE92098A1 (en) * 1996-07-31 1998-12-31 Schering Corp TRICYCLIC N-CYANOIMINES USEFUL AS PROTEIN TRANSFERASE INHIBITORS FARNESILO
KR100640672B1 (en) 1997-06-17 2006-11-02 파마코페이아 드럭 디스커버리, 인크. Benzpyrido Cycloheptane Compounds Useful for Inhibiting Farnesyl Protein Transferase and Pharmaceutical Compositions Comprising the Same
BR9916314A (en) 1998-12-18 2001-10-02 Schering Corp Tricyclic farnesyl transferase protein inhibitors

Also Published As

Publication number Publication date
CZ20011950A3 (en) 2001-12-12
NZ511878A (en) 2003-10-31
AR021718A1 (en) 2002-07-31
CA2354779A1 (en) 2000-06-29
WO2000037459A1 (en) 2000-06-29
IL143408A0 (en) 2002-04-21
JP2002533336A (en) 2002-10-08
CN1334811A (en) 2002-02-06
EP1140902A1 (en) 2001-10-10
CN1326850C (en) 2007-07-18
PE20001342A1 (en) 2000-12-09
PL348293A1 (en) 2002-05-20
NO20012961D0 (en) 2001-06-15
KR20010081116A (en) 2001-08-27
SK7592001A3 (en) 2002-03-05
CO5160350A1 (en) 2002-05-30
AU776558B2 (en) 2004-09-16
ZA200104233B (en) 2002-08-22
AU2030700A (en) 2000-07-12
HUP0202152A2 (en) 2002-10-28
BR9916314A (en) 2001-10-02
NO20012961L (en) 2001-08-16

Similar Documents

Publication Publication Date Title
TR200101754T2 (en) Farnesyl protein transferase inhibitors
DK1054874T3 (en) Substituted aminophenylisoxazoline derivatives useful as antimicrobial agents
ATE307119T1 (en) BICYCLIC PROTEIN FARNESYL TRANSFERASE INHIBITORS
DE69914893D1 (en) GLYCINAMIDE DERIVATIVES WITH FUNCTIONALIZED ALKYL AND ALKENYL SIDE CHAIN AS INHIBITORS OF FARNESYL TRANSFERASE
MXPA04001016A (en) Sulfonamide derivatives as gamma secretase inhibitors.
TR200101755T2 (en) Tricyclic farnesyl protein transferase inhibitors.
EP1184373A4 (en) Tricyclic compounds
DE69810760D1 (en) CONNECTIONS WITH CONDENSED RINGS, METHOD FOR THEIR PRODUCTION AND THEIR USE
BR0210746A (en) 6-'2- (phosphonomethoxy) alkoxy-pyrimidine derivatives having antiviral activity
WO1998052917A3 (en) Guanidinylation reagents
EP0994106A4 (en) Process for the preparation of carbamoyllated imidazole derivatives
DE69824722D1 (en) BENZIMIDAZOLE DERIVATIVES
DE69813554D1 (en) CYCLIC UREA AND LACTAM DERIVATIVES OF BENZO (5,6) CYCLOHEPTAPYRIDINES FOR USE AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR
ES2055651A1 (en) Amidines derived from 3-aminoethyl indoles for the treatment of migraines.
ECSP993273A (en) FARNESILO PROTEIN TRANSFERASE INHIBITORS
ATE312086T1 (en) PHENOXAZINE ANALOGUES FOR THE TREATMENT OF AMYLOIDOSE
PT81878B (en) PROCESS FOR THE PREPARATION OF UTILIZED 5-ARYL-DIHYDROPYRIDINES AS MEDICATIONS
TR199701289T2 (en) Esters of carbapenems
DK0667863T3 (en) 2-Perhaloalkyl-substituted benzimidazoles, their preparation and their use as pesticides
TR199901102T2 (en) Bicyclic amine derivatives.
ATE228359T1 (en) INHIBITION OF LEUKOTRIE BIOSYNTHESIS USING UREA DERIVATIVES
DE69817826D1 (en) BENZO [5,6] CYCLOHEPTA [1,2B] PYRIDINE DERIVATIVES APPLICABLE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS
ECSP993286A (en) FARNESILO PROTEIN TRANSFERASE INHIBITORS
BR0009079A (en) Process for the preparation of thiazolidine derivatives
TR200002577T2 (en) A method for revealing sulfanyl type endothelin receptor antagonists.